Michele Baccarani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michele Baccarani has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Martinelli
Hematology Unit, Ospedale S. Maria delle Croci, University of Bologna, 48100 Ravenna, Italy
20 shared publications - Giuseppe Visani
Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy
11 shared publications - Nicoletta Testoni
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, 40138 Bologna, Italy
10 shared publications - Pier Paolo Piccaluga
Biobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti, 9, 40138 Bologna, Italy
10 shared publications - Michele Malagola
Chair of Hematology, Unit of Blood Disease and Cell Therapy, Spedali Civili Hospital, Brescia, Italy
9 shared publications - Sante Tura
Hematology Unit, Istituto Seragnoli, Ospedale Sant’Orsola Malpighi, Bologna
9 shared publications
Latest Publications
- 1 December 2016
- Published by Elsevier in The Lancet Haematology
- Vol. 3 (12) , e554-e555
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
- 1 December 2016
- Published by Elsevier in The Lancet Haematology
- Vol. 3 (12) , e554-e555
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S211
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S211
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 7023
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
7023 Background: PON is a potent oral TKI active against native and mutated forms of BCR-ABL, including T315I. The ph 2 PACE study demonstrated that PON is highly active in heavily pretreated Ph+ leukemia pts. Methods: EPIC was an international, Ph 3 trial of PON (45 mg QD) vs IM (400 mg QD) in newly diagnosed CP-CML pts, with randomization stratified by Sokal risk score. The primary endpoint was major molecular response (MMR) rate at 1 yr. On 18 Oct 2013,EPIC was terminated due to accumulating vascular events in long-term follow-up of the PACE trial. Data as of 7 Oct 2013 are presented, median follow-up 3 (0.03-12) m. Results: At the time of analysis, 306 were randomized. Baseline characteristics were balanced for PON vs IM; median age 55 vs 52 yrs, 17% vs 16% high Sokal risk score, 62% vs 66% received prior hydroxyurea. Data on 267 treated pts were available (133 PON; 134 IM). 77% PON and 84% IM pts were ongoing; 14 PON and 6 IM pts D/C, (D/C due to AE; 9 PON pts [most common: thrombocytopenia and rash] and 1 IM pt). Response rates are in the table (evaluable pts). Most common (≥25%) all grade (G) AEs were PON: rash (36%), abdominal pain (32%), headache (31%), lipase increased (26%), myalgia (26%); IM: nausea (32%), muscle spasms (31%). 11% PON and 2% IM had G 3/4 thrombocytopenia; 3% PON and 8% IM had G 3/4 neutropenia. Serious AEs (SAEs) occurring in ≥3 PON pts were: pancreatitis (5 pts), atrial fibrillation (3), thrombocytopenia (3); no individual SAEs occurred in ≥3 IM pts. 9 (7%) PON and 5 (4%) IM pts experienced vascular occlusive events (SAEs: 6 PON, 1 IM). Updated data will be presented. Conclusions: While PON demonstrated early activity in frontline CP-CML, EPIC was terminated as its objectives could not be met with PON dose reductions implemented mid-trial due to safety observations in PACE. Further investigation of PON safety is warranted. PON remains an important treatment option for pretreated CML and Ph+ ALL pts in whom the need and benefit outweigh the risk. Clinical trial information: NCT01650805.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 7023
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
7023 Background: PON is a potent oral TKI active against native and mutated forms of BCR-ABL, including T315I. The ph 2 PACE study demonstrated that PON is highly active in heavily pretreated Ph+ leukemia pts. Methods: EPIC was an international, Ph 3 trial of PON (45 mg QD) vs IM (400 mg QD) in newly diagnosed CP-CML pts, with randomization stratified by Sokal risk score. The primary endpoint was major molecular response (MMR) rate at 1 yr. On 18 Oct 2013,EPIC was terminated due to accumulating vascular events in long-term follow-up of the PACE trial. Data as of 7 Oct 2013 are presented, median follow-up 3 (0.03-12) m. Results: At the time of analysis, 306 were randomized. Baseline characteristics were balanced for PON vs IM; median age 55 vs 52 yrs, 17% vs 16% high Sokal risk score, 62% vs 66% received prior hydroxyurea. Data on 267 treated pts were available (133 PON; 134 IM). 77% PON and 84% IM pts were ongoing; 14 PON and 6 IM pts D/C, (D/C due to AE; 9 PON pts [most common: thrombocytopenia and rash] and 1 IM pt). Response rates are in the table (evaluable pts). Most common (≥25%) all grade (G) AEs were PON: rash (36%), abdominal pain (32%), headache (31%), lipase increased (26%), myalgia (26%); IM: nausea (32%), muscle spasms (31%). 11% PON and 2% IM had G 3/4 thrombocytopenia; 3% PON and 8% IM had G 3/4 neutropenia. Serious AEs (SAEs) occurring in ≥3 PON pts were: pancreatitis (5 pts), atrial fibrillation (3), thrombocytopenia (3); no individual SAEs occurred in ≥3 IM pts. 9 (7%) PON and 5 (4%) IM pts experienced vascular occlusive events (SAEs: 6 PON, 1 IM). Updated data will be presented. Conclusions: While PON demonstrated early activity in frontline CP-CML, EPIC was terminated as its objectives could not be met with PON dose reductions implemented mid-trial due to safety observations in PACE. Further investigation of PON safety is warranted. PON remains an important treatment option for pretreated CML and Ph+ ALL pts in whom the need and benefit outweigh the risk. Clinical trial information: NCT01650805.
- 28 April 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (1) , 120-127
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1–14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1–7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37% in patients with AP-CML and 9% with BP-CML (22% and 5% in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.
- 28 April 2014
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (1) , 120-127
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1–14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1–7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37% in patients with AP-CML and 9% with BP-CML (22% and 5% in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.
- 31 May 2012
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (3) , 241-248
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
- 31 May 2012
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (3) , 241-248
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
- 15 September 2011
- Published by Societa Editrice Esculapio
Corso di Malattie del sangue e degli organi emolinfopoietici
- 15 September 2011
- Published by Societa Editrice Esculapio
Corso di Malattie del sangue e degli organi emolinfopoietici
- 30 September 2010
- Published by Elsevier in Leukemia Research
- Vol. 34 (9) , e246-e247
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration
- 30 September 2010
- Published by Elsevier in Leukemia Research
- Vol. 34 (9) , e246-e247
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration
- 31 December 2008
- Published by Elsevier in Leukemia Research
- Vol. 32 (12) , 1941-1943
Acute promyelocytic leukemia with amplification of PML-RARα rearrangement: Clinical implications
- 31 December 2008
- Published by Elsevier in Leukemia Research
- Vol. 32 (12) , 1941-1943
Acute promyelocytic leukemia with amplification of PML-RARα rearrangement: Clinical implications
- 30 June 2007
- Published by Elsevier in Clinical Leukemia
- Vol. 1 (4) , 223-228
Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter?
- 30 June 2007
- Published by Elsevier in Clinical Leukemia
- Vol. 1 (4) , 223-228
Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter?